Focused On-demand Library for Probable C-mannosyltransferase DPY19L2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Dpy-19-like protein 2; Protein dpy-19 homolog 2

Alternative UPACC:

Q6NUT2; A4FVC1; B4E191; Q3ZCX2; Q6UWG8; Q96LZ9


The Probable C-mannosyltransferase DPY19L2, also known as Dpy-19-like protein 2 or Protein dpy-19 homolog 2, plays a crucial role in human biology. It is primarily involved in the C-mannosylation of tryptophan residues on target proteins. This enzyme is essential during spermatogenesis, facilitating sperm head elongation and acrosome formation, as well as acrosome attachment to the nuclear envelope. Its unique functions underscore its importance in reproductive biology.

Therapeutic significance:

Given its pivotal role in spermatogenesis, particularly in sperm head elongation and acrosome formation, DPY19L2 is directly linked to Spermatogenic failure 9, a disorder characterized by infertility due to spermatogenesis defects. Understanding the role of DPY19L2 could open doors to potential therapeutic strategies for treating infertility issues related to spermatogenesis defects.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.